NDRA
ENDRA Life Sciences Inc. (NDRA) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Very high current and quick ratios indicate ample near-term liquidity versus peers, reducing refinancing pressure despite NDRA’s weak profitability profile.
Low debt-to-equity and net debt-to-EBITDA suggest limited balance-sheet leverage versus more indebted peers, supporting financial flexibility.
The extremely negative cash conversion cycle implies unusually fast working-capital turnover versus peers, which can support liquidity if operationally sustained.
Weaknesses
Negative return on invested capital shows NDRA is destroying capital versus profitable peers, indicating a structurally weak earnings engine.
Missing operating and gross margin disclosure limits transparency, but the available profitability signal still trails peers that generate positive operating leverage.
The absence of positive growth metrics in the provided data leaves NDRA without evidence of durable scale advantages versus better-growing peers.
Opportunities
If NDRA converts its strong liquidity into operating execution, it could narrow the gap with peers that currently outperform on profitability and capital efficiency.
Improving capital allocation from a low-leverage base could lift returns faster than peers burdened by heavier debt service.
A sustained normalization of working-capital dynamics could preserve cash and improve competitive resilience versus peers with slower conversion cycles.
Threats
Persistent negative ROIC raises the risk that peers with stronger unit economics will compound market-share and valuation advantages over time.
If liquidity is used to fund losses rather than growth, NDRA’s balance-sheet cushion could erode faster than better-capitalized peers.
Without demonstrated growth or segment concentration data, NDRA faces the threat of remaining a small, undifferentiated competitor versus more focused peers.
Overall Score
NDRA’s balance sheet appears liquid and lightly levered, but persistent negative capital returns leave its structural positioning weaker than profitable peers.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on ENDRA Life Sciences Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
